OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in ...

• In advanced-stage HL, reduction of chemotherapy or radiotherapy after a negative interim PET scan is probably beneficial for overall survival. • Treatment escalation with rituximab after a positive ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ...

AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Lytgobi is an FGFR inhibitor that received accelerated approval in 2022 to treat adults with previously treated, unresectable ...

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...